Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat.

Wargovich MJ, Chen CD, Jimenez A, Steele VE, Velasco M, Stephens LC, Price R, Gray K, Kelloff GJ.

Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):355-60.

2.

Growth kinetics and chemoprevention of aberrant crypts in the rat colon.

Wargovich MJ, Harris C, Chen CD, Palmer C, Steele VE, Kelloff GJ.

J Cell Biochem Suppl. 1992;16G:51-4. Review.

PMID:
1469905
3.

Inhibition of aberrant crypt foci by chemopreventive agents.

Olivo S, Wargovich MJ.

In Vivo. 1998 Mar-Apr;12(2):159-66. Review.

PMID:
9627797
4.
5.

Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program.

Steele VE, Moon RC, Lubet RA, Grubbs CJ, Reddy BS, Wargovich M, McCormick DL, Pereira MA, Crowell JA, Bagheri D, et al.

J Cell Biochem Suppl. 1994;20:32-54. Review.

PMID:
7616752
6.
7.

Aberrant crypts in human colonic mucosa: putative preneoplastic lesions.

Pretlow TP, O'Riordan MA, Pretlow TG, Stellato TA.

J Cell Biochem Suppl. 1992;16G:55-62. Review.

PMID:
1361589
9.

Role of aberrant crypt foci in understanding the pathogenesis of colon cancer.

Bird RP.

Cancer Lett. 1995 Jun 29;93(1):55-71. Review.

PMID:
7600544
12.

Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents.

Greenwald P, Kelloff GJ, Boone CW, McDonald SS.

Cancer Epidemiol Biomarkers Prev. 1995 Oct-Nov;4(7):691-702. Review.

13.

[Aberrant crypt foci as biomarkers in chemoprevention for colorectal cancer].

Katsuki S, Oui M, Takayama T, Takahashi Y, Shuichi N, Niitsu Y.

Nihon Geka Gakkai Zasshi. 1998 Jun;99(6):379-84. Review. Japanese.

PMID:
9695076
14.

New agents for cancer chemoprevention.

Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet RA, Doody LA, Malone WF, Hawk ET, Sigman CC.

J Cell Biochem Suppl. 1996;26:1-28. Review.

PMID:
9154166
15.

Mechanistic considerations in the evaluation of chemopreventive data.

Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet RA, Greenwald P, Hawk ET, Fay JR, Sigman CC.

IARC Sci Publ. 1996;(139):203-19. Review.

PMID:
8923032
16.

Colon cancer chemoprevention with ginseng and other botanicals.

Wargovich MJ.

J Korean Med Sci. 2001 Dec;16 Suppl:S81-6. Review.

17.
18.

Surrogate endpoint biomarker assays in phase II chemoprevention clinical trials.

Lipkin M, Bhandari M, Hakissian M, Croll W, Wong G.

J Cell Biochem Suppl. 1994;19:47-54. Review.

PMID:
7823605
19.

Screening for chemopreventive (anticarcinogenic) compounds in rodents.

Boone CW, Steele VE, Kelloff GJ.

Mutat Res. 1992 Jun;267(2):251-5. Review.

PMID:
1376427

Supplemental Content

Support Center